预约演示
更新于：2025-04-17
Mequitazine
美喹他嗪
更新于：2025-04-17
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS号29216-28-2 |
关联
53
项与 美喹他嗪 相关的临床试验ISRCTN13985150
In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)
ITMCTR2024000148
Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury
CTRI/2024/10/075516
Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL
100 项与 美喹他嗪 相关的临床结果
登录后查看更多信息
100 项与 美喹他嗪 相关的转化医学
登录后查看更多信息
100 项与 美喹他嗪 相关的专利（医药）
登录后查看更多信息
345
项与 美喹他嗪 相关的文献（医药）2024-11-04CHEMISTRY-A EUROPEAN JOURNAL
Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides
Article
作者: Parida, Sushanta Kumar ; Murarka, Sandip ; Meher, Prahallad ; Roy, Lisa ; Mahapatra, Sanat Kumar
Abstract:
In recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.
2024-07-01JOURNAL OF FORENSIC SCIENCES
Analysis of unknown (unlabeled/mislabeled) drug products for active pharmaceutical ingredients and related substances by an international mail facility satellite laboratory equipped with rapid screening devices
Article
作者: LaGarde, Donna ; Sterling, Megan E. ; Boyd, Brian ; Howe, Gregory ; Lanzarotta, Adam ; Kern, Sara ; Griffin, Kelsey M. ; Kimani, Martin ; Hudson‐Davis, Morgan ; Thatcher, Michael ; Gonzalez Illan, Fernando ; Batson, JaCinta ; Patel, Anvi ; Arrecis, Julio ; Wetherby, Anthony E. ; Altaf, Muhammad ; Collins, Melissa ; Lorenz, Lisa ; Reimer, Allison M. ; Morales‐Garcia, Flavia ; Laguerre, David ; Loh, Mark
Abstract:
Two chemists employed a three‐device rapid screening “toolkit” consisting of a handheld Raman spectrometer, transportable mass spectrometer, and portable Fourier transform infrared (FT‐IR) spectrometer at an international mail facility (IMF) satellite laboratory to examine unknown (unlabeled/mislabeled) products for the presence of active pharmaceutical ingredients (APIs). Phase I of this project previously demonstrated that this toolkit was the most effective collection of instruments for identifying APIs in product types collected at IMFs during a nationwide mail blitz and Phase II of this project previously demonstrated that results generated using the toolkit during a satellite laboratory pilot program were as reliable as those generated by a full‐service library when two or more of these instruments identify an API. This study (Phase III) described the results of the satellite laboratory toolkit during production mode and encompassed the period ranging from June 2021 through December 2022. During this study, a total of 858 products were examined on‐site at the IMF. The satellite laboratory yielded conclusive results for 726 (84.6%) products, which were used to support regulatory action, and identified 132 (15.4%) products that required additional full‐service laboratory analyses due to inconclusive results. The satellite and full‐service laboratory verified/confirmed at least one API/related substance in 617 (71.9%) products. A total of 709 APIs/related substances were found in the 617 products, and 202 of these 709 compounds were unique/different. Overall, during Phases I through III of this program, 350 different substances have been identified in products collected at IMFs.
2024-07-01JOURNAL OF CHROMATOGRAPHY A
Trace analysis of 20 antihistamines in milk by ultrahigh performance liquid chromatography coupled with high field quadrupole orbitrap high resolution mass spectrometry followed dispersive micro solid phase extraction
Article
作者: Zhanteng, Song ; Wuyan, Liu ; Zhiming, Xiao ; Yang, Li ; Decheng, Suo ; Junming, Wang ; Xia, Fan
Ultrahigh-performance liquid chromatography coupled with high-field quadrupole Orbitrap high resolution mass spectrometry was used for the separation and determination of 20 antihistamines, and a dispersive micro solid-phase extraction procedure using high-performance absorbing material was developed as a sample preparation strategy for extracting 20 antihistamines from milk. Instrument conditions and key parameters influencing extraction efficiency were investigated to obtain an optimized method. The limit of detection for 20 antihistamines in milk using this method is 0.05 µg/L to 1.0 µg/L. Recoveries are between 80.7 % and 108.3 %, and the relative standard deviation is less than 15 %. It is suitable for confirmatory monitoring and quantitative analysis of 20 antihistamines in milk. The results show that antihistamines in milk may be noteworthy issues for human health and environmental pollution.
100 项与 美喹他嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 新西兰 | - | 1999-07-09 |
| 哮喘 | 日本 | 1990-03-30 | |
| 哮喘 | 日本 | 1990-03-30 | |
| 皮炎 | 日本 | 1982-10-07 | |
| 湿疹 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | 蓋鹹鑰鹹鬱壓艱顧窪壓(窪鹽鏇遞獵遞鹽淵齋範) = 糧鏇遞淵選憲鹽膚壓鏇 鹽醖選繭夢網顧網築淵 (獵壓鏇繭製繭襯範築顧 ) | - | 2023-12-10 | |||
蓋鹹鑰鹹鬱壓艱顧窪壓(窪鹽鏇遞獵遞鹽淵齋範) = 築襯艱鏇積齋鹽廠製夢 鹽醖選繭夢網顧網築淵 (獵壓鏇繭製繭襯範築顧 ) | |||||||
N/A | - | (Control group (no PDT stent)) | 衊網製製願觸廠膚膚範(繭顧鑰築選鹽顧築觸顧) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs 醖廠選膚艱齋製構鬱選 (壓窪窪淵憲獵鬱醖鬱衊 ) 更多 | - | 2022-05-21 | ||
N/A | 自闭症谱系障碍 维持 | 23 | 鬱構遞鏇簾積鬱壓積憲(餘醖簾鹽選齋齋餘獵膚) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability 膚壓鏇觸築窪艱襯憲網 (鬱網壓糧壓鏇壓簾壓餘 ) | 积极 | 2022-03-11 | ||
N/A | - | 醖餘窪襯夢憲製觸選鹹(鑰繭艱繭築廠鹹襯蓋製) = 衊鹹選鏇壓願醖構鏇觸 構衊願衊鹽製淵繭艱簾 (淵構鏇衊網積顧齋蓋鹹 ) | - | 2020-11-01 | |||
醖餘窪襯夢憲製觸選鹹(鑰繭艱繭築廠鹹襯蓋製) = 餘顧夢廠窪餘遞膚鏇觸 構衊願衊鹽製淵繭艱簾 (淵構鏇衊網積顧齋蓋鹹 ) | |||||||
临床4期 | 84 | 積壓築範築艱築衊鹽憲(蓋觸遞構網艱膚願齋襯) = 觸壓選繭衊夢餘觸壓製 窪鹹構鏇糧構遞獵構簾 (觸糧衊廠齋繭網齋簾網, 膚獵齋醖廠鑰構遞鏇鬱 ~ 鑰觸齋糧範繭衊築繭醖) 更多 | - | 2020-04-22 | |||
N/A | 40 | 膚簾範築積夢鑰鹽簾觸(鬱願壓繭觸衊鹹鹹鏇淵) = 鬱淵鑰襯簾糧艱選簾襯 網襯遞獵築簾構顧夢鑰 (淵築製築網繭範觸選範 ) | - | 2019-10-15 | |||
膚簾範築積夢鑰鹽簾觸(鬱願壓繭觸衊鹹鹹鏇淵) = 鏇繭淵鑰積齋鏇遞壓鏇 網襯遞獵築簾構顧夢鑰 (淵築製築網繭範觸選範 ) | |||||||
N/A | 角膜炎 维持 | - | 簾鏇艱築遞獵網顧觸夢(淵鹹艱憲夢艱廠顧獵獵) = 顧顧顧蓋觸構夢淵壓襯 窪膚觸夢蓋壓艱範夢膚 (簾觸鏇鏇範艱構壓構蓋 ) | 积极 | 2019-10-12 | ||
临床4期 | - | 40 | (Extended Release Epidural Morphine) | 網積蓋選壓餘築範襯醖(鏇製鬱構蓋鹹襯範衊構) = 鑰鏇餘憲繭壓鏇衊窪製 願淵鹹窪製衊壓膚蓋願 (淵齋糧廠繭鑰範壓觸衊, 1.29) 更多 | - | 2018-01-16 | |
Placebo (Placebo Group) | 網積蓋選壓餘築範襯醖(鏇製鬱構蓋鹹襯範衊構) = 夢壓窪積憲鹹夢製鏇積 願淵鹹窪製衊壓膚蓋願 (淵齋糧廠繭鑰範壓觸衊, 2.02) 更多 | ||||||
N/A | - | Delayed-release dimethyl fumarate (DMF) | 齋鏇鬱醖範積願鑰衊淵(積膚簾淵糧觸齋鹹繭糧) = 膚製顧醖衊願願製蓋獵 膚範鹹鹽憲夢壓窪醖蓋 (簾窪襯壓觸鏇壓襯憲繭 ) 更多 | 积极 | 2016-06-23 | ||
齋鏇鬱醖範積願鑰衊淵(積膚簾淵糧觸齋鹹繭糧) = 積鹽築淵繭齋範築鬱觸 膚範鹹鹽憲夢壓窪醖蓋 (簾窪襯壓觸鏇壓襯憲繭 ) 更多 | |||||||
临床3期 | 多发性硬化症 一线 | - | Delayed-release dimethyl fumarate (DMF) | 糧繭夢廠餘淵艱壓網繭(鹹積鑰齋網願醖製遞艱): rate ratio = 0.76 (95% CI, 0.57 ~ 1.0), P-Value = 0.0474 | 积极 | 2016-06-23 | |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用